| Ticker | GERN |
|---|---|
| ISIN | US3741631036 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. T...
El precio actual de Geron Corporation (GERN) es de 1,50 , con una variación del 0,00%.
Geron Corporation opera en el sector Healthcare, industria Biotechnology.